Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://www.nejm.org" to "https://www.nejm.org") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
||
| Line 14: | Line 14: | ||
[[Category:Thrombotic thrombocytopenic purpura medications]] | [[Category:Thrombotic thrombocytopenic purpura medications]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 18:00, 3 February 2019
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Preliminary data
Thrombotic thrombocytopenic purpura
- Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. link to original article PubMed